Leader/Supervisor: Dr Georgia Terzoudi

Ph.D. Student: Aggeliki Nikolakopoulou, MSc

Company/Co-funder: ELECTA

Radiation Therapy (RT) is often used in conjunction with other therapies such as chemotherapy or tumour removal surgery as an integral part of both curative and palliative treatments for cancer. While RT is one of the most effective single modalities in cancer therapy, it can have significant side effects both during and after treatment, which can impact both the quality and the duration of life. Although rapid technological advances have led to a more precise delivery of radiation dose and to a decreased risk of side effects, there is still a significant need for personalized treatment to be achieved through the development of predictive tools that may guide therapy decisions.  The objectives of this project are the prediction of individual radiosensitivity in clinical practice, the investigation of the potential of combining radiation therapy with G2/M cell cycle checkpoint abrogators in vitro, as well as the evaluation of the efficiency of advanced radiotherapy techniques such as VMAT and IMRT, using phantoms in conjunction with cytogenetic techniques.